Diet-induced obesity accelerates acute lymphoblastic leukemia progression in two murine models.
Obesity is associated with an increased incidence of many cancers, including leukemia, although it is unknown whether leukemia incidence is increased directly by obesity or rather by associated genetic, lifestyle, health, or socioeconomic factors. We developed animal models of obesity and leukemia to test whether obesity could directly accelerate acute lymphoblastic leukemia (ALL) using BCR/ABL transgenic and AKR/J mice weaned onto a high-fat diet. Mice were observed until development of progressive ALL. Although obese and control BCR/ABL mice had similar median survival, older obese mice had accelerated ALL onset, implying a time-dependent effect of obesity on ALL. Obese AKR mice developed ALL significantly earlier than controls. The effect of obesity was not explained by WBC count, thymus/spleen weight, or ALL phenotype. However, obese AKR mice had higher leptin, insulin, and interleukin-6 levels than controls, and these obesity-related hormones all have potential roles in leukemia pathogenesis. In conclusion, obesity directly accelerates presentation of ALL, likely by increasing the risk of an early event in leukemogenesis. This is the first study to show that obesity can directly accelerate the progression of ALL. Thus, the observed associations between obesity and leukemia incidence are likely to be directly related to biological effects of obesity.
Yun
Jason P
JP
Division of Endocrinology, Childrens Hospital Los Angeles, Los Angeles, CA 90027, USA.
Behan
James W
JW
Heisterkamp
Nora
N
Butturini
Anna
A
Klemm
Lars
L
Ji
Lingyun
L
Groffen
John
J
Müschen
Markus
M
Mittelman
Steven D
SD
D052242:Adiponectin / Q000097:blood; D017668:Age of Onset; D000818:Animals; D004032:Diet; D004195:Disease Models, Animal; D018450:Disease Progression; D016313:Genes, abl / Q000235:genetics; D006801:Humans; D007328:Insulin / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D020738:Leptin / Q000097:blood; D051379:Mice; D008806:Mice, Inbred AKR; D008822:Mice, Transgenic; D009765:Obesity / Q000097:blood / Q000150:complications*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications* / Q000235:genetics
D052242:Adiponectin; D007328:Insulin; D015850:Interleukin-6; D020738:Leptin
Blood. 1997 Nov 1;90(9):3438-43
9345027
Science. 1988 Jan 29;239(4839):502-4
2829354
J Exp Med. 1980 Mar 1;151(3):542-52
6244357
Int J Obes (Lond). 2008 Nov;32(11):1716-9
18725892
JAMA. 2005 Jan 12;293(2):203-11
15644547
Breast Cancer Res. 2007;9(6):R91
18162139
Curr Opin Pharmacol. 2009 Aug;9(4):351-69
19665429
J Immunol. 1984 Jun;132(6):2948-54
6202767
Nature. 1990 Mar 15;344(6263):251-3
2179728
BMJ. 2007 Dec 1;335(7630):1134
17986716
Diabetes. 1988 Sep;37(9):1163-7
3044882
N Engl J Med. 2003 Apr 24;348(17):1625-38
12711737
Int J Cancer. 2008 Mar 15;122(6):1418-21
18027857
Prev Med. 1993 May;22(3):409-22
8327421
Eur J Cancer. 2010 May;46(7):1223-31
20335016
Leukemia. 1992 Nov;6(11):1134-42
1434795
Cancer Res. 2009 Oct 1;69(19):7867-74
19773440
Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11138-42
1763029
Lancet. 2008 Feb 16;371(9612):569-78
18280327
J Clin Oncol. 2007 May 20;25(15):2063-9
17513811
Int J Cancer. 1992 Feb 1;50(3):500-4
1310491
Br J Haematol. 1998 Aug;102(3):740-5
9722301
Blood. 2009 Oct 29;114(18):3803-12
19721009
Cytokine. 2009 Dec;48(3):203-11
19665393
FASEB J. 2003 Apr;17(6):690-2
12586746